Cinqair® (reslizumab)

Covered: Cinqair (reslizumab) is authorized only as the FDA‑approved add‑on maintenance treatment for severe eosinophilic asthma in adults (≥18); non‑FDA indications and pediatric use are excluded. Key requirements: initial approval requires blood eosinophils ≥400 cells/µL within 4 weeks (or prior to another mAb), ≥3 months of prior ICS plus another controller, evidence of uncontrolled asthma by ≥2 steroid-treated exacerbations or ≥1 hospitalization/ER visit or FEV1 <80% or FEV1/FVC <0.80 or worsening with OCS taper, and prescription/consultation by an allergist/immunologist/pulmonologist (initial approval 6 months); reauthorization requires ≥6 months of prior Cinqair, continued ICS therapy, documented clinical response, and renewals are for 12 months (recommended dosing 3 mg/kg IV every 4 weeks).

"Medical record documentation of at least 3 consecutive months of combination therapy with an inhaled corticosteroid plus one additional asthma controller/maintenance medication prior to initiation."